Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)

Next Previous
X
Search
Trial Profile

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linrodostat (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary) ; Rucaparib (Primary) ; Ipilimumab
  • Indications Adenocarcinoma; Endometrial cancer; Gastric cancer; Oesophageal cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FRACTION-Gastric Cancer; FRACTION-GC
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 08 Mar 2024 This trial has been completed Italy in according to European Clinical Trials Database record.
    • 09 Jun 2023 Status changed from active, no longer recruiting to completed.
    • 18 Apr 2023 The trial has been completed in Netherlands,, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top